Evidence map›Paper›PMID 42409778›Full record

ArticleSignal transduction and targeted therapy2026

Targeting endoplasmic reticulum export disrupts metabolic resilience in multiple myeloma.

Utku Horzum, Herbert Oberacher, Margot Haun, Stephan Geley, Monica Roman-Trufero, Holger Auner, Agnieszka Martowicz, Gerold Untergasser, Eberhard Gunsilius, Wolfgang Willenbacher and 4 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Utku HorzumInstitute of Pathophysiology, Medical University of Innsbruck, Innsbruck, Austria. utku.horzum@i-med.ac.at.ORCID http://orcid.org/0000-0002-6747-3043
Herbert OberacherInstitute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-0963-8268
Margot HaunInstitute of Pathophysiology, Medical University of Innsbruck, Innsbruck, Austria.
Stephan GeleyInstitute of Pathophysiology, Medical University of Innsbruck, Innsbruck, Austria.
Monica Roman-TruferoDivision of Hematology, Lausanne University Hospital, Lausanne, Switzerland.ORCID http://orcid.org/0009-0007-7650-1441
Holger AunerDivision of Hematology, Lausanne University Hospital, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-4040-0642
Agnieszka MartowiczDepartment of Hematology and Oncology, Internal Medicine V, Comprehensive Cancer Center Innsbruck (CCCI), Austrian Comprehensive Cancer Network (ACCN), Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-5781-9995
Gerold UntergasserDepartment of Hematology and Oncology, Internal Medicine V, Comprehensive Cancer Center Innsbruck (CCCI), Austrian Comprehensive Cancer Network (ACCN), Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-3430-119X
Eberhard GunsiliusDepartment of Hematology and Oncology, Internal Medicine V, Comprehensive Cancer Center Innsbruck (CCCI), Austrian Comprehensive Cancer Network (ACCN), Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0003-1327-2921
Wolfgang WillenbacherDepartment of Hematology and Oncology, Internal Medicine V, Comprehensive Cancer Center Innsbruck (CCCI), Austrian Comprehensive Cancer Network (ACCN), Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0001-7702-1721
Hamdullah YanikDepartment of Basic Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1066-552X
Gunes EsendagliDepartment of Basic Oncology, Cancer Institute, Hacettepe University, Ankara, Turkey.ORCID http://orcid.org/0000-0003-4865-2377
Dominik WolfDepartment of Hematology and Oncology, Internal Medicine V, Comprehensive Cancer Center Innsbruck (CCCI), Austrian Comprehensive Cancer Network (ACCN), Tyrolean Cancer Research Institute (TKFI), Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-4761-075X
Hesso FarhanInstitute of Pathophysiology, Medical University of Innsbruck, Innsbruck, Austria. hesso.farhan@i-med.ac.at.ORCID http://orcid.org/0000-0002-0889-8463

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/ESP634Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/FG20Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) 10.55776/P36600Norges Forskningsråd (Research Council of Norway) 302452
6 · The paper itself

Abstract

Multiple myeloma (MM) is characterized by the production and secretion of large quantities of immunoglobulins, making this malignancy highly dependent on mechanisms that maintain cellular proteostasis. While significant clinical progress has been made by targeting the degradative branch of proteostasis, much less attention has been given to the biosynthetic branch. In this study, we demonstrated that inhibiting COPII-dependent endoplasmic reticulum (ER) export induces cell death in several MM cell lines and primary patient-derived cells. The induction of cell death was dependent on the secretory status of MM cells. Blocking ER export in secretory MM cells caused the accumulation of misfolded proteins, which activated ER-associated degradation (ERAD). Consequently, we observed an ERAD-dependent increase in the levels of free cytosolic amino acids and a subsequent activation of mTORC1 signaling. Simultaneously, we observed mitochondrial dysfunction. These alterations resulted in a mismatch between the increased energy demand due to mTORC1 activation, and the disrupted energy supply from mitochondrial impairment. This energetic imbalance results in homeostatic collapse and cell death of secretory MM cells. The therapeutic potential of the concept was demonstrated in two in vivo myeloma models. These findings suggest that the ER export machinery could be a promising therapeutic target in multiple myeloma.

Indexed as

Endoplasmic ReticulumEndoplasmic Reticulum-Associated DegradationMechanistic Target of Rapamycin Complex 1Multiple MyelomaAnimalsCell Line, TumorHumansMiceMitochondriaProteotoxic StressMechanistic Target of Rapamycin Complex 1

Identifiers

PMID42409778
PMCPMC13338250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.